A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease

Table 4

Circulating levels of the selected markers before and after treatment in the randomized groups. Median (25, 75 percentiles) are given.

Marker	Baseline		3 months
	Saxagliptin ()	Placebo ()	Saxagliptin ()	Placebo ()	Δp
TNF-α (pg/mL)	1.61 (1.36, 1.96)	1.23 (1.04, 1.49)	1.54 (1.32, 1.64)	1.33 (1.16, 1.59)	0.429
MCP-1 (pg/mL)	117 (100, 149)	118 (94, 173)	114 (99, 116)	113 (88, 166)	0.792
IL-18 (pg/mL)	297 (192, 493)	399 (307, 500)	342 (177, 422)	419 (305, 522)	0.009
Fractalkine (pg/mL)	604 (535, 649)	520 (455, 628)	577 (451, 627)	504 (443, 622)	0.931

Δp denotes difference in relative change between groups (Mann–Whitney U test); for intragroup change (Wilcoxon signed-rank test).